0000000000462659

AUTHOR

P. Cavalla

showing 2 related works from this author

A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple s…

2016

Abstract Introduction Depression and anxiety are common among patients with multiple sclerosis (MS) and are frequently present at the time of MS diagnosis. Methods POSIDONIA was a 12-month, observational, prospective study conducted in Italy to evaluate the impact of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosed MS. The Hospital Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) subscale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale – Revised (IES-R) were used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was used as a measure…

MalePsychometricsAnxietyHospital Anxiety and Depression Scale0302 clinical medicineImmunologic FactorMultiple sclerosis Disease-modifying treatment Emotional burden Anxiety DepressionMultiple SclerosiDisease-modifying treatment030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)DepressionMiddle AgedPsychiatric Status Rating ScaleTreatment OutcomeItalyNeurologyAnxietyFemaleSettore MED/26 - Neurologiamedicine.symptomPsychologyPsychometricHumanAdultmedicine.medical_specialtyMultiple SclerosisMood DisorderPsychometricsAdolescentLogistic Model03 medical and health sciencesYoung AdultRating scalemedicineHumansImmunologic FactorsAgedPsychiatric Status Rating ScalesMood Disordersmedicine.diseaseProspective StudieLogistic ModelsMood disordersPhysical therapyEmotional burdenObservational studyNeurology (clinical)030217 neurology & neurosurgery
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct